Boehringer Ingelheim Acquires Pharmaxis’ Phase 1 Anti-inflammatory Drug Candidate

News   May 22, 2015

 
Boehringer Ingelheim Acquires Pharmaxis’ Phase 1 Anti-inflammatory Drug Candidate
 
 
 

RELATED ARTICLES

PPD and Quotient Sciences Form Innovative Partnership to Accelerate Pediatric Drug Development

News

Will shorten timelines, reduce costs and simplify contracting process in pediatric programs.

READ MORE

Concept Life Sciences appoints New Group Programme Manager and US Head of Sales

News

Key leadership appointments support integration of the Group and expansion in the US market.

READ MORE

Safety and Efficacy of MERS Treatment Confirmed in Phase I Trial

News

An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE